Login to Your Account



NewCo News

Soricimed Makes 'Shrew'd Play in Cancer Treatment, Diagnosis

By Jennifer Boggs
Managing Editor

Monday, October 1, 2012

Drugs derived from the venom of unusual species is hardly a novelty in biotech. There's Amylin Pharmaceuticals Inc.'s Gila monster-derived diabetes drug Byetta (exenatide) and investigational drugs GxMTx4, a nontoxic peptide from spider venom from Rose Pharmaceuticals for Duchenne's muscular dystrophy, and Paion AG's recently divested desmoteplase, a plasminogen activator based on the saliva from a vampire bat.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription